CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

RFA: Inlyta for Metastatic Renal Cell Carcinoma

Note: The pCODR Provincial Advisory Group, PAG, has submitted a Request for Advice for the Final Recommendation for this drug and indication originally posted on March 7, 2013. The original axitinib (Inlyta) pCODR review can be found  on the Inlyta for metastatic renal cell carcinoma (mRCC) details page: https://www.cadth.ca/inlyta-metastatic-renal-cell-carcinoma-mrcc-details.

Project Number pCODR RFA 0001
Brand Name Inlyta (RFA)
Generic Name Axitinib
Tumour Type Genitourinary
Indication Metastatic Renal Cell Carcinoma
Review Status Notification to Implement Issued
Pre Noc Submission
NOC Date
Manufacturer Pfizer Canada Inc.
Sponsor pCODR Provincial Advisory Group
Submission Date April 18, 2017
Submission Type Request for Advice
Prioritization Requested
Stakeholder Input Deadline ‡ May 2, 2017
pERC Meeting June 16, 2017
Clarification Please note that the June pERC meeting was conducted over two days. The target for the posting of pERC Initial Recommendation remains as June 29, 2017.
Final Recommendation Issued (target date) June 29, 2017
Notification to Implement Issued June 30, 2017

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.